Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-699-4 | CAS number: 68-96-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Effects on fertility
Description of key information
OECD 422: NOAEL (offspring development) = 1000 mg/kg bw; NOAEL (female, systemic toxicity) = 300 mg/kg bw; NOAEL (female, reproductive toxicity) = 300 mg/kg bw; NOEL (male, systemic and reproductive toxicity) = 1000 mg/kg bw (Barraclough 2017)
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- March - July 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- Adopted 28 July 2015
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:WI (Han)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Margate, UK
- Age at study initiation: 10 -11 weeks (males), 9 - 10 weeks (females)
- Weight at start of dosing: 280.4 - 409.2 g (males), 186.4 - 242.4 g (females)
- Fasting period before study: not applicable
- Housing: housed in groups (up to four animals/cage by sex [both sexes pre-pairing and males post-pairing] or with one female and one male [pairing]), individually (mated females), or with their litter (lactation)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: up to 20 days
DETAILS OF FOOD AND WATER QUALITY:
No contaminants were present in diet and water at levels which might have interfered with achieving the objective of the study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): within 19 - 25°C
- Humidity (%): 30 - 70%
- Air changes (per hr): 15 - 20
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: To: 11 April - 9 June 2016 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.1% Myrj S-50-PA, 1.0% Klucel LF add 100% with 0.9% physiological saline solution
- Details on exposure:
- Formulations were prepared weekly.
The test item formulations were formulated as a suspension in 0.1% Myrj S-50-PA, 1.0% Klucel LF add 100% with 0.9% physiological saline solution. The formulations were stored at room temperature (15 to 25°C) in a sealed container, protected from light. - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: up to 10 days
- Proof of pregnancy: vaginal plug / sperm in vaginal smear referred to as day 0 of pregnancy
- After successful mating each pregnant female was caged: individually
- Animals were paired on the day following 14 days of dosing. During the pairing phase, one male was housed for up to 10 days with one female from the same dose group. Three animals of Group 1; one animal of Group 2; one animal of group 3; and one animal of Group 4 were paired on the day following 19 days in the pre-pairing phase (Day 20 of the study). - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Suspensions of 0.1 and 100 mg/mL were previously found to be homogenous and stable for 10 days at 15 to 25°C.
Formulations prepared for use in Week 1 were analysed to determine homogeneity. Formulations are normally considered to be homogeneous if the coefficient of variation (CV) of the results is ≤ 6.0% and the homogeneity results are within ± 10% of the mean. The results were within these criteria.
Formulations prepared for use in Weeks 1, 3 and 6 of the study were analysed to determine achieved concentration. The target range for the preparation of the
formulations was 90 to 110% of nominal. Results were within this range.
Test article was not detected in the Group 1 control samples. - Duration of treatment / exposure:
- Males: 42 days
Females: up to 64 days - Frequency of treatment:
- once daily
- Details on study schedule:
- - Age at mating of the mated animals in the study: 14-15 weeks
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Control
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Low dose
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Intermediate
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- High dose
- No. of animals per sex per dose:
- Males: 10
Females: 13 (control), 11 (dosing groups); more than 10 female rats per group were included to ensure 10 females/group showed a regular estrous
cycle before dosing commenced - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
High dose: A high dose level of 1000 mg/kg/day was considered a suitable dose level as it would be well tolerated, although an effect on reproduction was expected, based on the findings of the dose range finder study.
Intermediate dose: An intermediate dose level of 300 mg/kg/day was expected to be a no observed adverse effect level (NOAEL) for systemic toxicity, and no effects on reproduction were expected.
Low dose: A low dose level of 100 mg/kg/day was anticipated to be the NOEL for systemic toxicity. - Positive control:
- not applicable
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes, for signs of ill health or overt toxicity
- Time schedule: at the beginning and end of working day (in addition, post dosing observations, upon return to the home cage and approximately 2 hours after dosing
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once daily
BODY WEIGHT: Yes
- Time schedule for examinations:
males: prior to dosing, on the first day of dosing, afterwards weekly, and prior to necropsy at day 43;
females: prior to dosing, on the first day of dosing, afterwards weekly prior to pairin; until confirmation of mating; on gestation day (GD) 0, 7, 14, 20; and on lactation day (LD) 1, 4, 7, and 13; and prior to necropsy on lactation day 14;
FOOD CONSUMPTION: Yes
- males: twice weekly
- females: twice weekly prior to pairing, then daily from gestation day 0 to 20 and from lactation day 1 to 13 - Oestrous cyclicity (parental animals):
- Estrous cycle determination:
- during predose phase, from one week after arrival until the day prior to dosing and daily vaginal lavage samples were taken from females from the start of dosing until the confirmation of mating - Sperm parameters (parental animals):
- Testis weight, epididymis weight, qualitative testis examination
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
- If yes, maximum of 10 pups/litter (5/sex/litter as nearly as possible); excess pups were killed and discarded.
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain, physical abnormalities, anogenital distance (AGD), presence of nipples/areolae in male pups
GROSS EXAMINATION OF DEAD PUPS:
- macroscopic examination and recording of all lesions - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals on day 43 of the study (Post-pairing day 15)
- Maternal animals: All surviving animals on lactation day (LD) 14 or day 26 post coitum
GROSS NECROPSY
- Macroscopic examinations were conducted and all lesions were recorded.
HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated in Table [1] were prepared for microscopic examination and weighed, respectively. - Postmortem examinations (offspring):
- SACRIFICE
Surplus pups were culled on PND (post natal day) 4. Remaining pups were sacrificed at PND 13.
Blood was sampled for thyroid hormone analysis. After termination, macroscopic examinations were conducted, and all lesions were recorded. - Statistics:
- Data for each sex was analyzed separately, unless stated otherwise. Except when otherwise stated, tests were performed using a two-sided risk and were considered significant when p≤0.05.
Body weight, body weight gains, food consumption (gestation and lactation phases), absolute organ weights, organ:terminal body weight ratios, and terminal body weights were analyzed using analysis of variance (ANOVA).
Male and female mating, fecundity, and fertility indices were analyzed using a one-sided lower tail Fisher’s exact test.
Mean numbers of estrous cycles and mean cycle length were analyzed using the Kruskal-Wallis and Wilcoxon rank sum test.
Percent pregnant, percent delivering, and gestation index were analyzed using a one-sided lower tail Fisher’s exact test.
Percent of females with stillborn pups was analyzed using a one-sided upper tail Fisher’s exact test.
The number of pups delivered, live-born pups, implantation sites and live-birth index, Day 4 viability index, duration of gestation, and percent post-implantation loss were analyzed using the Kruskal-Wallis and Wilcoxon rank sum test.
Pup weights (male, female, and combined) were analyzed using analysis of covariance (ANCOVA), with litter size as the covariate.
Live pups/litters with live pups were analyzed using the Kruskal-Wallis and Wilcoxon rank sum test. - Reproductive indices:
- Males:
Mating index % = (Number of males mating with at least 1 female / Number of males cohabitated with at least 1 female) x 100
Fecundity index % = (Number of males impregnating at least 1 female / Number of males mating with at least 1 female) x 100
Fertility Index % = (Number of males impregnating at least 1 female / Number of males cohabitated with at least 1 female) x 100
Females:
Mating index % = Mated females/females cohabited (excluding females sacrificed during Cohabitation) x 100
Fecundity index % = Pregnant females/mated females (excluding females with an undetermined pregnancy status) x 100
Fertility index % = Pregnant females/females cohabited (excluding females sacrificed during Cohabitation or with an undetermined pregnancy status) x 100
Gestation index % = (Number of females with live pups / Number of pregnant females) x 100
% post-implantation loss = (Number of implantations - number of live embryos) / Number of implantations) x 100 - Offspring viability indices:
- % live birth index (litter) = (Number of live pups per litter at birth / Number of pups born per litter) X 100
% live birth index (mean) = Sum of live pups per group at birth / Total number of litters
% Viability index 1-4 (litter) = (Number of pups alive Day 4 before culling / Number of pups born alive) X 100
% Viability index 1-4 (mean) = Sum of % litters on Day 4 before culling in each group / Total number of litters - Clinical signs:
- no effects observed
- Description (incidence and severity):
- The clinical observations noted included isolated instances of physical injury to the tip of the tail, teeth pallor, sores, lesions and staining of the skin and/or fur, and thin fur; these were noted throughout dose groups, including the control group; as such, they were considered low incidence findings observed in this species and were unrelated to test item toxicity.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- All parameters, including those statistically significant, were considered unrelated to test item administration as they were small in magnitude or lacked a dose-dependent response.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - Two females administered 1000 mg/kg/day test substance showed higher than expected creatinine and urea values, when compared with controls.
- elevated cholesterol levels for all test substance-treated females compared to controls (p<0.01 - p<0.05), without dose-related response
Cholesterol females [mmol/L]: (Control: 1.9 +- 0.37; Low dose: 2.5 +- 0.32***; Intermediate dose: 2.6 +- 0.3***; High dose: 2.4 +- 0.3***)
*** P<=0.001; ANOVA and Dunnett's - Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- All parameters, including those statistically significant, were considered unrelated to test item administration as they were small in magnitude or lacked a dose-dependent response.
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- An increased incidence and/or severity of tubular basophilia and/or cortical scar were present in females administered 100, 300, or 1000 mg/kg/day. Cortical scar was correlated with depressed foci, noted at necropsy. Basophilia, tubule was characterized by focal or multifocal groups of tubules in the renal cortex, with basophilic epithelium, crowding of nuclei, more intense staining of the cells, and occasionally thickened basement membranes, and often with an inflammatory cell infiltrate. Cortical scar was characterized by focal lesions in the cortex, with fibroblast proliferation and collagen deposition, generally inconspicuous tubular elements, and occasionally cystic tubules, with pigment and few inflammatory cells. (Table 2)
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- - TSH levels were elevated for all test item-treated females compared with controls (p<0.01), without dose-related response. Further, no effects on organ weight and no histopathological changes were observed.
TSH µlU/mL (Control: 0.46 +- 0.295; Low dose: 1.38 +- 1.135**; Intermediate dose: 1.16 +- 0.621**; High dose: 1.71 +- 2.536**)
**P<=0.01; ANOVA und Dunnett's - Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Description (incidence and severity):
- Qualitative testis examination did not indicate any abnormalities in the integrity of the various cell types present within the different stages of the spermatogenic cycle.
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- No test substance-related effects on mating, fecundity, or fertility were noted.
The number of implantation sites evident for females administered 1000 mg/kg/day was slightly lower than controls, and percentage post-implantation loss was statistically higher in this group, compared with controls (p<0.01). Slightly higher percentage post-implantation losses was also evident for females administered 300 or 1000 mg/kg/day compared with controls (p<0.05 or p<0.01 respectively). This resulted in slightly lower mean number of pups per litter in 300 or 1000 mg/kg/day litters, compared with control (-12 and -20% respectively) [see table 3]. Furthermore, a slightly higher percentage of male pups were noted in 1000 mg/kg/day litters, compared with controls (+27%), although statistical significance was never achieved. In the absence of any adverse clinical observations or higher rates of litter mortality after birth, these slight differences, compared with controls, were considered not to have represented adverse effects on the offspring. - Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: No treatment related effects observed
- Remarks on result:
- other: systemic and reproductive toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: non-neoplastic
- Remarks on result:
- other: systemic toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- reproductive performance
- Remarks on result:
- other: reproductive toxicity
- Dose descriptor:
- NOEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- reproductive performance
- Remarks on result:
- other: reproductive toxicity
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- System:
- urinary
- Organ:
- kidney
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- In the absence of a convincing dose-related response, the statistically significantly increased body weights of pups from 100 or 300 mg/kg/day litters following the cull on PND 4 were considered to have arisen incidentally and were unrelated to administration of Hydroxyprogesterone.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Other effects:
- not specified
- Description (incidence and severity):
- A slightly higher percentage of male pups were noted in 1000 mg/kg/day litters, compared with controls (+27%), although statistical significance was never achieved.
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- other: no adverse effects observed
- Reproductive effects observed:
- no
- Conclusions:
- In conclusion, once daily oral gavage administration of 100, 300, or 1000 mg/kg/day test substance to male rats for 42 days and to female rats for up to 64 days (pre-pairing, throughout gestation, and during the first 2 weeks of lactation) did not result in any test item-related effects in males; as such, 1000 mg/kg/day is considered the no observed effect level (NOEL) for males for systemic and reproductive toxicity. Microscopic kidney changes noted for females administered 100 or 300 mg/kg/day were confined to slightly lower grades of severity compared with high dose females, and in the absence of any notable changes in blood creatinine and urea, were considered not adverse; as such, 300 mg/kg/day is considered the no observed adverse effect level (NOAEL) for females for systemic toxicity. Due to the only slight changes observed in number of implantation sites at 1000 mg/kg/day and in post-implantation losses at 300 and 1000 mg/kg/day and the high standard deviations the NOAEL for females for reproductive toxicity was established at 300 mg/kg/day.
The NOAEL for offspring development was considered to be 1000 mg/kg/day. - Executive summary:
In a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test according to OECD TG 422 Hydroxyprogesteron was administered to 10 Wistar rats/sex/dose by gavage at dose levels of 100, 300, or 1000 mg/kg bw/day for at least 42 days at a constant dose volume of 10 mL/kg. For details on general toxicity please refer to section 7.5 (Repeated Dose Toxicity, Main study, OECD 422).
The control article (vehicle) was 0.1% Myrj S-50-PA, 1.0% Klucel LF add 100% with 0.9% physiological saline solution. The test item was formulated as a suspension. Formulations prepared for use in Weeks 1, 3, and 6, including the vehicle control were analysed for accuracy.
Before the start of dosing, all females were screened for regular estrous cycles; only females with regular estrous cycles were included in the study. On Day 3 of dosing, additional females were added to the study because not all females initially included showed a regular estrous cycle during the predose phase. Therefore, the number of females on study increased to 13, 11, 11, and 11 (0, 100, 300, or 1000 mg/kg/day, respectively).
In accordance with the test guideline, males were dosed once daily for 42 consecutive days (two weeks prior to mating, during the mating period and approximately two weeks post-mating) and sent to necropsy on Day 43. Females were dosed for up to 64 days (two weeks prior to mating, during the mating period and until Day post-partum) and sent to necropsy on Lactation Day (LD) 14.
For pups, clinical observations, litter size, sex, and body weight were recorded.
Ano-genital distance was recorded on Postnatal Day (PND) 4, and nipple retention was recorded for male pups on PND 13. One pup/sex/litter from each dose group was selected for collection of thyroid weights and processing for microscopic examinations.
Assessment of toxicity in adults was based on clinical observations, neurobehavioral assessments, body weights, food consumption, estrous cycling, mating, fertility and pregnancy indices, offspring development, and anatomic pathology. On the day of necropsy, blood samples were withdrawn for clinical pathology (adults) and thyroid hormone assessments (adults and offspring). Complete necropsies were performed on all animals, and any macroscopic abnormalities were noted. Organ weights were recorded for all adults and microscopic examinations were conducted for selected animals.
The number and length of estrous cycles were unaffected by administration of Hydroxyprogesterone, and no effect on mating, fecundity, or fertility indices occurred.
A slightly lower number of implantation sites were observed for females administered 1000 mg/kg/day and a slightly higher percentage of post-implantation losses for females administered 1000 or 300 mg/kg/day, were noted, resulting in slightly lower mean pups/litter for these dose groups. A slightly higher percentage of male pups were noted in 1000 mg/kg/day litters. No effect on thyroid hormones was noted on PND 4, and no thyroid weight changes, macroscopic abnormalities, or microscopic changes were noted in the thyroids of pups.
In conclusion, once daily oral gavage administration of 100, 300, or 1000 mg/kg/day Hydroxyprogesterone to male rats for 42 days and to female rats for up to 64 days (pre-pairing, throughout gestation, and during the first 2 weeks of lactation) did not result in any test item-related effects in males; as such, 1000 mg/kg/day is considered the no observed effect level (NOEL) for males for systemic and reproductive toxicity.
Microscopic kidney changes noted for females administered 100 or 300 mg/kg/day were confined to slightly lower grades of severity compared with high dose females, and in the absence of any notable changes in blood creatinine and urea, were considered not adverse; as such, 300 mg/kg/day is considered the no observed adverse effect level (NOAEL) for females for systemic and reproductive toxicity.
The NOAEL for offspring development was considered to be 1000 mg/kg/day, based on the slightly higher number of male offspring noted at this dose level, compared with controls.
Reference
- No statistical significant effect on TSH of pups on PND 4 or 13
Table 2:
Incidence of Selected Kidney Findings - Terminal Sacrifice
|
- = Finding not present; 1 = Minimal; 2 = Slight; 3 = Moderate.
Table 3:
|
xxx
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- OECD guideline study
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
17-Hydroxyprogesterone (17-OHP) is a metabolite of progesterone and as such an endogenous intermediate in steroid hormone synthesis. Thus, a progestational effect might be expected from 17-OHP following systemic availability.
Regarding TRGS 905 (version 12.03.2020 and the justification document for Steroid Hormones, version Sept 1999) OHPA is classified as gestagen (group 7) with a reproduction toxicity RF= 1A and RD=1B (CLP), but 17-OHP is not listed here.
For the assessment of hazard on reproductive toxicity after oral application a combined repeated dose toxicity study with the reproduction toxicity screening according to OECD TG 422 with 17-OHP can be used. This reproductive toxicity study is scored with reliability 1 (Klimisch 1997). For details on general toxicity please refer to section 7.5 (Repeated Dose Toxicity, Main study, OECD 422).
In a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test according to OECD TG 422 Hydroxyprogesterone was administered to 10 Wistar rats/sex/dose by gavage at dose levels of 100, 300, or 1000 mg/kg bw/day for at least 42 days at a constant dose volume of 10 mL/kg.
The control article (vehicle) was 0.1% Myrj S-50-PA, 1.0% Klucel LF add 100% with 0.9% physiological saline solution. The test item was formulated as a suspension. Formulations prepared for use in Weeks 1, 3, and 6, including the vehicle control were analysed for accuracy.
Before the start of dosing, all females were screened for regular estrous cycles; only females with regular estrous cycles were included in the study. On Day 3 of dosing, additional females were added to the study because not all females initially included showed a regular estrous cycle during the predose phase. Therefore, the number of females on study increased to 13, 11, 11, and 11 (0, 100, 300, or 1000 mg/kg/day, respectively).
In accordance with the test guideline, males were dosed once daily for 42 consecutive days (two weeks prior to mating, during the mating period and approximately two weeks post-mating) and sent to necropsy on Day 43. Females were dosed for up to 64 days (two weeks prior to mating, during the mating period and until Day post-partum) and sent to necropsy on Lactation Day (LD) 14.
For pups, clinical observations, litter size, sex, and body weight were recorded.
Ano-genital distance was recorded on Postnatal Day (PND) 4, and nipple retention was recorded for male pups on PND 13. One pup/sex/litter from each dose group was selected for collection of thyroid weights and processing for microscopic examinations.
Assessment of toxicity in adults was based on clinical observations, neurobehavioral assessments, body weights, food consumption, estrous cycling, mating, fertility and pregnancy indices, offspring development, and anatomic pathology. On the day of necropsy, blood samples were withdrawn for clinical pathology (adults) and thyroid hormone assessments (adults and offspring). Complete necropsies were performed on all animals, and any macroscopic abnormalities were noted. Organ weights were recorded for all adults and microscopic examinations were conducted for selected animals.
The number and length of estrous cycles were unaffected by administration of Hydroxyprogesterone, and no effect on mating, fecundity, or fertility indices occurred.
A slightly lower number of implantation sites were observed for females administered 1000 mg/kg/day and a slightly higher percentage of post-implantation losses for females administered 1000 or 300 mg/kg/day, were noted, resulting in slightly lower mean pups/litter for these dose groups. A slightly higher percentage of male pups were noted in 1000 mg/kg/day litters. No effect on thyroid hormones was noted on PND 4, and no thyroid weight changes, macroscopic abnormalities, or microscopic changes were noted in the thyroids of pups.
In conclusion, once daily oral gavage administration of 100, 300, or 1000 mg/kg/day Hydroxyprogesterone to male rats for 42 days and to female rats for up to 64 days (pre-pairing, throughout gestation, and during the first 2 weeks of lactation) did not result in any test item-related effects in males; as such, 1000 mg/kg/day is considered the no observed effect level (NOEL) for males for systemic and reproductive toxicity.
Microscopic kidney changes noted for females administered 100 or 300 mg/kg/day were confined to slightly lower grades of severity compared with high dose females, and in the absence of any notable changes in blood creatinine and urea, were considered not adverse; as such, 300 mg/kg/day is considered the no observed adverse effect level (NOAEL) for females for systemic and reproductive toxicity.
The NOAEL for offspring development was considered to be 1000 mg/kg/day, based on the slightly higher number of male offspring noted at this dose level, compared with controls.
Due to the low gestagenic potency of 17-OHP and the limited oral bioavailability of OHPA very rare clinical data of both compounds are reported.
Regarding TRGS 905 (version 12.03.2020 and the justification document for Steroid Hormones, version Sept 1999) OHPA is classified as gestagen (group 7) with a reproduction toxicity RF= 1A and RD=1B (CLP), but 17-OHP is not listed here. RTECS shows a reproductive toxicity entry for 17-OHP based on a case study in 1960 reporting on genital abnormality of a child which mother was treated with 250 mg intramuscularly during pregnancy every second week (Leibow, 1960). It is unclear whether 17-OHP or its caproate OHPC was administered, the latter introduced for medical use in 1954/55 and typically applied until today as intramuscular depot with 250 mg/ml (Proluton®, Makena®) to prevent preterm birth. Nevertheless, a derived TDLo 65 mg/kg for 17-OHP is cited in RTECS.
Other case control studies revealed no conclusive evidence for higher incidences of congenital abnormalities or neural-tube defects after therapeutical administration of hydroxyprogesterone (no further data on substance identity) during pregnancy (Leibow, 1960; Medveczky, 2004). Consequently, after a history of precautionary labeling for therapeutic exposure of progestational drugs more recent epidemiologic analyses, animal studies and basic scientific principles disproved the risks and led 1987 to the FDA removing the warning label on oral contraceptives regarding nongenital malformation (Brent, 2005). Recent publications conclude even for the therapeutic use during pregnancy with almost no concern or signal for reproductive toxicity in association with progesterone or 17-hydroxyprogesterone (Christian et.al, 2007; Golub et al., 2006; Elizur et.al., 2008).
Based on CLP no classification for reproductive toxicity is warranted for 17-OHP.
References:
Leibow SG, Gardner LI, Pediatrics 1960, July:151-160
Maskova et al., Cent Eur J Med 2011; 6(4):435-441
Medveczky, Pharmacoepidem Drug Safety 2004; 13:443-455
Brent, Birth Defects Research (Part A) 2005; 73
Elizur et.al., Fertility and Sterility 2008; 89 (6):1595-1602
Christian et.al., J Mat-Fet Neonat Med 2007; 20(2):89-112
Golub et al., Birth Defects Res B Dev Reprod Toxicol, 2006 Oct;77(5):455-70
Effects on developmental toxicity
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the study results a classification according to Regulation (EC) No. 1272/2008 (CLP) is not required.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.